Other (Income)/Deductions - Net (Details) - USD ($) $ in Millions		3 Months Ended
		Apr. 02, 2017	Apr. 03, 2016
Other Income and Expenses [Abstract]
Royalty-related income		$ (7)	$ (7)
Net gain on sale of assets	[1]	0	(33)
Foreign currency loss	[2]	2	9
Other, net	[3]	(5)	1
Other (income)/deductions—net		$ (10)	$ (30)

[1] For the three months ended April 3, 2016, represents the net gain on the sale of certain manufacturing sites and products as part of our operational efficiency initiative.

[2] Primarily driven by costs related to hedging and exposures to certain emerging market currencies.

[3] For the three months ended April 2, 2017, primarily includes a settlement refund and reimbursement of legal fees related to costs incurred by Pharmaq prior to the acquisition in 2015, as well as interest income and other miscellaneous income.